title: Valsartan use in pediatric hypertension.
abstract: Hypertension affects up to 5% of school-aged children and is defined by an average systolic or diastolic blood pressure greater than the 95th percentile for age, sex and height. In prepubertal children a secondary cause for hypertension including renal disease, coarctation of the aorta or endocrine disease should be excluded by appropriate evaluation. The incidence and prevalence of essential hypertension in adolescents has increased together with the increase in obesity and now accounts for at least 50% of hypertension in this age group. Many children with primary hypertension and most children with secondary causes for hypertension require drug therapy. There are numerous drug classes that are presently used to treat hypertensive pediatric patients, which include β-blockers, peripheral α-blockers, direct vasodilators, ACE inhibitors, calcium channel blockers, diuretics and ARBs. This article will review the pharmacology of the ARB valsartan with respect to its efficacy, tolerability and safe use in hypertensive pediatric patients.
authors: Division of Pediatric Nephrology, The Children's Hospital of Philadelphia, 34th Street & Civic Center Blvd, Philadelphia, PA 19104, USA. meyersk@email.chop.edu
authors: Kevin E C
authors: KE
authors: Meyers
authors: Brittany
authors: B
authors: Behar
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D002648:Child; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D014633:Valine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine